Sytse C van Beek1, André N Vis2, Noor van Ginkel3, Tom J N Hermans4, Dennie Meijer3, Joost L Boormans1, Jens Voortman5, Laura Mertens6. 1. Department of Urology, Erasmus University Medical Centre, Rotterdam, The Netherlands. 2. Department of Urology, Amsterdam University Medical Center, Location VUmc, De Boelelaan 1117, Postbus 7057, 1007 MB, Amsterdam, The Netherlands. a.vis@amsterdamumc.nl. 3. Department of Urology, Amsterdam University Medical Center, Location VUmc, De Boelelaan 1117, Postbus 7057, 1007 MB, Amsterdam, The Netherlands. 4. Department of Urology, Maastricht University Medical Centre, Maastricht, The Netherlands. 5. Department of Medical Oncology, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands. 6. Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Abstract
OBJECTIVES: To assess survival of patients with muscle-invasive bladder cancer (MIBC) who underwent radical cystectomy (RC) with or without neo-adjuvant chemotherapy (NAC) according to the pathological response at RC. METHODS: 965 patients with MIBC (cT2-4aN0M0) who underwent RC with or without NAC were analyzed. Among the collected data were comorbidity, clinical and pathological tumor stage, tumor grade, nodal status (y)pN, and OS. Case-control matching of 412 patients was performed to compare oncological outcomes. Kaplan-Meier curves were created to estimate OS for patients who underwent RC with or without NAC, and for those with complete response (pCR), partial response (pPR), or residual or progressive disease (PD). RESULTS: Patients with a pCR or pPR at RC, with or without NAC, had better OS than patients who had PD (both p values < 0.001). Moreover, the incidence of pCR was significantly higher in patients receiving NAC prior to RC than in patients undergoing RC only (31% versus 15%, respectively; p < 0.001). Case-control matching displayed better OS of patients who underwent RC with NAC, median survival not reached, than of those who underwent RC only, median 4.5 years (p = 0.023). CONCLUSIONS: This study showed that patients with MIBC who underwent NAC with RC had a significant better OS than those who underwent RC only. The proportion of patients with a pCR was higher in those who received NAC and RC than in those who were treated by RC only. The favorable OS rate in the NAC and RC cohort was probably attributed to the higher observed pCR rate.
OBJECTIVES: To assess survival of patients with muscle-invasive bladder cancer (MIBC) who underwent radical cystectomy (RC) with or without neo-adjuvant chemotherapy (NAC) according to the pathological response at RC. METHODS: 965 patients with MIBC (cT2-4aN0M0) who underwent RC with or without NAC were analyzed. Among the collected data were comorbidity, clinical and pathological tumor stage, tumor grade, nodal status (y)pN, and OS. Case-control matching of 412 patients was performed to compare oncological outcomes. Kaplan-Meier curves were created to estimate OS for patients who underwent RC with or without NAC, and for those with complete response (pCR), partial response (pPR), or residual or progressive disease (PD). RESULTS: Patients with a pCR or pPR at RC, with or without NAC, had better OS than patients who had PD (both p values < 0.001). Moreover, the incidence of pCR was significantly higher in patients receiving NAC prior to RC than in patients undergoing RC only (31% versus 15%, respectively; p < 0.001). Case-control matching displayed better OS of patients who underwent RC with NAC, median survival not reached, than of those who underwent RC only, median 4.5 years (p = 0.023). CONCLUSIONS: This study showed that patients with MIBC who underwent NAC with RC had a significant better OS than those who underwent RC only. The proportion of patients with a pCR was higher in those who received NAC and RC than in those who were treated by RC only. The favorable OS rate in the NAC and RC cohort was probably attributed to the higher observed pCR rate.
Authors: Roland Seiler; Hussam Al Deen Ashab; Nicholas Erho; Bas W G van Rhijn; Brian Winters; James Douglas; Kim E Van Kessel; Elisabeth E Fransen van de Putte; Matthew Sommerlad; Natalie Q Wang; Voleak Choeurng; Ewan A Gibb; Beatrix Palmer-Aronsten; Lucia L Lam; Christine Buerki; Elai Davicioni; Gottfrid Sjödahl; Jordan Kardos; Katherine A Hoadley; Seth P Lerner; David J McConkey; Woonyoung Choi; William Y Kim; Bernhard Kiss; George N Thalmann; Tilman Todenhöfer; Simon J Crabb; Scott North; Ellen C Zwarthoff; Joost L Boormans; Jonathan Wright; Marc Dall'Era; Michiel S van der Heijden; Peter C Black Journal: Eur Urol Date: 2017-04-05 Impact factor: 20.096
Authors: Jamie S Pak; Christopher R Haas; Christopher B Anderson; G Joel DeCastro; Mitchell C Benson; James M McKiernan Journal: Urol Oncol Date: 2021-04-14 Impact factor: 3.498
Authors: Praful Ravi; Gregory R Pond; Leonidas N Diamantopoulos; Christopher Su; Ajjai Alva; Rohit K Jain; William P Skelton; Sumati Gupta; Jonathan D Tward; Kathleen M Olson; Parminder Singh; Camilla M Grunewald; Guenter Niegisch; Jae-Lyun Lee; Andrea Gallina; Marco Bandini; Andrea Necchi; Matthew Mossanen; Bradley A McGregor; Catherine Curran; Petros Grivas; Guru P Sonpavde Journal: BJU Int Date: 2021-05-18 Impact factor: 5.588